Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 260

1.

Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial.

Kerstjens HA, Disse B, Schröder-Babo W, Bantje TA, Gahlemann M, Sigmund R, Engel M, van Noord JA.

J Allergy Clin Immunol. 2011 Aug;128(2):308-14. doi: 10.1016/j.jaci.2011.04.039. Epub 2011 Jun 2.

PMID:
21636120
2.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
3.

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma.

Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM.

J Allergy Clin Immunol. 2011 Aug;128(2):315-22. doi: 10.1016/j.jaci.2011.06.004.

PMID:
21807250
4.

Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma.

Beeh KM, Moroni-Zentgraf P, Ablinger O, Hollaenderova Z, Unseld A, Engel M, Korn S.

Respir Res. 2014 Jun 3;15:61. doi: 10.1186/1465-9921-15-61.

5.

Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study.

Vogelberg C, Engel M, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, Sigmund R, Downie J, Nething K, Vevere V, Vandewalker M.

Respir Med. 2014 Sep;108(9):1268-76. doi: 10.1016/j.rmed.2014.06.011. Epub 2014 Jul 17.

6.

A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD.

Voshaar T, Lapidus R, Maleki-Yazdi R, Timmer W, Rubin E, Lowe L, Bateman E.

Respir Med. 2008 Jan;102(1):32-41. Epub 2007 Nov 8.

7.

Tiotropium 5microg via Respimat and 18microg via HandiHaler; efficacy and safety in Japanese COPD patients.

Ichinose M, Fujimoto T, Fukuchi Y.

Respir Med. 2010 Feb;104(2):228-36. doi: 10.1016/j.rmed.2009.11.011. Epub 2009 Dec 6.

8.

Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma.

Timmer W, Moroni-Zentgraf P, Cornelissen P, Unseld A, Pizzichini E, Buhl R.

Respir Med. 2015 Mar;109(3):329-38. doi: 10.1016/j.rmed.2014.12.005. Epub 2014 Dec 27.

10.

The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.

van Noord JA, Cornelissen PJ, Aumann JL, Platz J, Mueller A, Fogarty C.

Respir Med. 2009 Jan;103(1):22-9. doi: 10.1016/j.rmed.2008.10.002. Epub 2008 Nov 20.

11.

Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.

Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.

Clin Ther. 2011 Dec;33(12):1974-84. doi: 10.1016/j.clinthera.2011.11.009.

PMID:
22177371
12.

Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.

Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.

Clin Ther. 2012 Aug;34(8):1655-66.e5. doi: 10.1016/j.clinthera.2012.06.005. Epub 2012 Jul 11.

PMID:
22789766
13.
14.
15.

Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial.

Tashkin DP.

Expert Rev Respir Med. 2010 Jun;4(3):279-89. doi: 10.1586/ers.10.23. Review.

PMID:
20524910
16.

A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators.

N Engl J Med. 2008 Oct 9;359(15):1543-54. doi: 10.1056/NEJMoa0805800. Epub 2008 Oct 5.

17.

Tiotropium in asthma poorly controlled with standard combination therapy.

Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, Sigmund R, Seibold W, Moroni-Zentgraf P, Bateman ED.

N Engl J Med. 2012 Sep 27;367(13):1198-207. Epub 2012 Sep 2.

18.

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.

Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium.

Ann Intern Med. 2007 Apr 17;146(8):545-55. Epub 2007 Feb 19.

PMID:
17310045
19.

Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD.

Abrahams R, Moroni-Zentgraf P, Ramsdell J, Schmidt H, Joseph E, Karpel J.

Respir Med. 2013 Jun;107(6):854-62. doi: 10.1016/j.rmed.2013.02.005. Epub 2013 Mar 13.

20.

Supplemental Content

Support Center